Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation.

Cotugno M, Nosso G, Saldalamacchia G, Vitagliano G, Griffo E, Lupoli R, Angrisani L, Riccardi G, Capaldo B

Acta diabetologica14 Sept 2014Cited by 19 (Europe PMC)

PMID25218924DOI10.1007/s00592-014-0644-5PepBankPUB-25218924

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and severe obesity, adding liraglutide gave an average weight loss of 5 kg at 12 months, much less than the 38 kg after bariatric surgery.
In plain wordsIn adults with diabetes and severe obesity, liraglutide users lost less weight over 12 months than people who had bariatric surgery.
Peptide
Liraglutide
Outcome
DecreaseWeight loss at 12 months
Study
n = 31
Comparator
Bariatric surgery
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Weight loss
5 kg
liraglutide
Weight loss
38 kg
bariatric surgery
Source sentences
Summary
Twelve months after treatment, average weight loss was 38 ± 15 kg among bariatric surgery patients, and 5 ± 8 kg in medical treatment group (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective evaluation was conducted in 31 patients with type 2 diabetes and severe obesity who had undergone bariatric surgery and in 31 patients with type 2 diabetes and comparable body weight who had added liraglutide to their background medical treatment in the period 2009-2013.
Report a problemFND-2521892401
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and severe obesity, glycemic control improved in the liraglutide group, with greater improvement after bariatric surgery.
In plain wordsIn adults with diabetes and severe obesity, blood sugar control improved with liraglutide, but improved more after bariatric surgery.
Peptide
Liraglutide
Outcome
Direction not reportedGlycemic control at 12 months
Study
n = 31
Comparator
Bariatric surgery
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Glycemic control improved in both groups with greater improvement in bariatric surgery patients.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective evaluation was conducted in 31 patients with type 2 diabetes and severe obesity who had undergone bariatric surgery and in 31 patients with type 2 diabetes and comparable body weight who had added liraglutide to their background medical treatment in the period 2009-2013.
Report a problemFND-2521892402
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and severe obesity, the UKPDS risk score decreased with liraglutide but stayed higher than after bariatric surgery.
In plain wordsIn adults with diabetes and severe obesity, heart risk scores fell with liraglutide but stayed higher than after bariatric surgery.
Peptide
Liraglutide
Outcome
DecreaseUKPDS cardiovascular risk score
Study
n = 31
Comparator
Bariatric surgery
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
The UKPDS risk score decreased in both groups, although it remained higher in medical treatment than in bariatric surgery patients (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective evaluation was conducted in 31 patients with type 2 diabetes and severe obesity who had undergone bariatric surgery and in 31 patients with type 2 diabetes and comparable body weight who had added liraglutide to their background medical treatment in the period 2009-2013.
Report a problemFND-2521892403
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and severe obesity, almost 60% of liraglutide patients met the glycated hemoglobin target below 7% and lost at least 5% of body weight.
In plain wordsIn adults with diabetes and severe obesity, almost 60% of liraglutide users reached the blood sugar target and lost at least 5% of body weight.
Peptide
Liraglutide
Outcome
Not applicableProportion reaching HbA1c <7% and losing at least 5% body weight
Study
n = 31
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Responders
≈ 60%
liraglutide, HbA1c <7% and weight loss >=5%
Source sentences
Summary
Of note, almost 60 % of patients on liraglutide met the target of glycated hemoglobin <7 % (53 mmol/mol) and lost ≥5 % of body weight.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective evaluation was conducted in 31 patients with type 2 diabetes and severe obesity who had undergone bariatric surgery and in 31 patients with type 2 diabetes and comparable body weight who had added liraglutide to their background medical treatment in the period 2009-2013.
Report a problemFND-2521892404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.